Ipsen SA
http://www.ipsen.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Finance Watch: SPAC Deals Emerge As IPO Market Goes Quiet Again
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.
Pivotal Period For Irlab And Its Parkinson’s Pipeline
The Swedish biotech is well positioned with soon-to-be late-stage clinical assets, commercial validation and a strong pipeline, new CEO Richard Godfrey tells Scrip.
Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.
Genfit To Pick Up Second Liver Failure Candidate In €40m Versantis Buyout
Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Clementia Pharmaceuticals, Inc.
- Epizyme, Inc.
- Ipsen Bioscience, Inc.
- Sterix
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation